v3.24.1.u1
STOCKHOLDERS’ DEFICIT
12 Months Ended
Dec. 31, 2023
Stockholders’ Deficit [Abstract]  
STOCKHOLDERS’ DEFICIT

NOTE 5 – STOCKHOLDERS’ DEFICIT

Preferred Stock

The Company has authorized 10,000,000 preferred shares, with a par value of $0.001 per share. The Company issued 1,000,000 shares of its Series A Preferred Series stock to IHG in fulfillment of the purchase agreement. These shares are convertible at a ratio of 100 shares of the common stock of the Company for each share of preferred stock of the Company.

Common Stock

In July 2022, the Company’s authorized common stock was increased from 700,000,000 to 2,000,000,000 shares, with an effective date of the Amendment to the Articles of Incorporation of August 5, 2022. There was no change in the shares outstanding of either the common stock or preferred stock as a result of the increase.

During the year ended December 31, 2022, the Company issued shares of its common stock as follows:

  • 405,010,195 shares for conversion of $619,211 principal and interest on convertible notes payable.
  • 12,795,700 shares for exercise of previously issued warrants at $0.0023 per share. The exercise price was revised to $0.0023 per share from $0.25 per share as per antidilution provision of the warrant agreement. The warrants were exercised on a cashless or “net” basis. Accordingly, the Company did not receive any proceeds from the warrant exercise. The cashless exercise of the warrants resulted in the cancellation of previously issued warrants to purchase an aggregate of 118,800 shares of common stock.

 

During the year ended December 31, 2023, the Company issued shares of its common stock as follows:

  • 845,162,311 shares for conversion of $200,432 principal and interest on convertible note payable.
  • 71,250,000 shares valued at $266,063 as consideration for financing fees for loans made to the Company.
  • 25,000,000 shares valued at $100,000 ($0.004 per share) as partial consideration for a media consulting contract.
  • 56,788,923 shares for exercise of previously issued warrants at $0.0128 per share. The exercise price was revised to $0.00062 per share from $0.25 per share as per antidilution provision of the warrant agreement. The warrants were exercised on a cashless or “net” basis. Accordingly, the Company did not receive any proceeds from the warrant exercise. The cashless exercise of the warrants resulted in the cancellation of previously issued warrants to purchase an aggregate of 148,000 shares of common stock.

Common Stock to be issued

On July 1, 2023, the Board of Directors approved a plan for the issuance of shares of the Company’s common stock as follows: 1,000,000 shares each to Directors of the Company; 2,000,000 shares each to new officers of the Company; 1,000,000 shares each to new advisors of the Company. The Board authorized, as of July 1, 2023, the issuance of an aggregate 8,000,000 shares of its common stock under the approved plan to four individuals, valued at $3,200 ($0.0004 per share), based on the trading price of the Company’s common stock as of the date of grant. As of December 31, 2023, the shares have not been issued and the Company has charged $3,200 as stock based compensation expense and recorded the shares to be issued as common stock to be issued on the accompanying financial statements.